Nagy S, Argyelan G, Molnár J, Kawase M, Motohashi N
Faculty of Medicine, Albert Szent-Györgyi Medical University, Szeged, Hungary.
Anticancer Res. 1996 Jul-Aug;16(4A):1915-8.
One of the biggest challenges in health care is the fight against tumors. Some phenothiazines have antitumor activity on HEp-2 tumor cells. In this study, we tested the antitumor effects of three series such as 10-nonsubstituted phenothiazines, 10-[n-(phthalimido)alkyl]-2-substituted-10H-phenothiazines and 1-(chloroethyl)-3-(2-substituted-10H-phenothiazines-10-yl)alkyl-1-ureas with H, Cl and CF3 substitution at position C2. The TCID50 of phenothiazines was affected by the H, Cl and CF3 at C2. Trifluoromethyl derivative of phenothiazine showed potent (R = CF3, TCID50 = 4.7 micrograms) activity, whereas the chlorine derivative of phenothiazine (R = Cl, TCID50 = 62.5 micrograms) had a relatively weak effect. In the group of 10-[n-(phthalimido)alkyl]-2-substituted-10H-phenothiazines, 10-[3-(phthalimido)propyl]-10H-phenothiazine (R = H, n = 3, TCID50 = 11.5 micrograms), 10-[4-(phthalimido)butyl]-10H-phenothiazine (R = H, n = 4, TCID50 = 7.8 micrograms) and 10-[3-(phthalimido)propyl]-2-trifluoromethyl-10H- phenothiazine (R = CF3, n = 3, TCID50 = 11.5 micrograms) was very effective. On the other hand, TCID50 of 10-[3-(phthalimido)propyl]-2-chloro-10H-phenothiazine (R = Cl, n = 3, TCID50 = 75.0 micrograms), 10-[4-(phthalimido)butyl]-2-chloro-10H-phenothiazine (R = Cl, n = 4, TCID50 = 31.3 micrograms) and 10-[4-(phthalimido)butyl]-2-trifluoromethyl-10H-phenothiazine (R = CF3, n = 4, TCID50 = 50.0 micrograms) were about 4-8 times less effective than 10-[4-(phthalimido)butyl]-10H-phenothiazine (R = H, n = 4, TCID50 = 7.8 micrograms). Among six 1-(chloroethyl)-3- (2-substituted-10H-phenothiazin-10-yl)alkyl-1-ureas, two chlorine compounds such as 1-(2-chloroethyl)-3-(2-chloro-10H-phenothiazin-10-yl)propyl-1-urea (R = Cl, n = 3, TCID50 = 6.3 micrograms), 1-(2-chloroethyl)-3-(2-chloro-10H-phenothiazin-10-yl) butyl-1-urea (R = Cl, n = 4, TCID50 = 7.8 micrograms), and 1-(2-chloroethyl)-3-(2-trifluoromethyl-10H-phenothiazin-10-yl)buty l-1-ur ea (R = CF3, n = 4, TCID50 = 7.8 micrograms) were significantly active. Tests showed that the substitution at 2C position apparently affected the anti-HEp-2 tumor cell activity; that the length of the aliphatic side chain at 10N contributes to the anti-tumor activity; and that the TCID50 values of the derivatives with butylene group (-C4H8-) were lower than those with propylene group (-C3H6-) except 10-[4-(phthalimido) butyl]-2-trifuoromethyl-10H-phenothiazine and 1-(2-chloroethyl)-3-(2-chloro-10H-pheno-thiazin-10-yl) butyl-1-urea.
医疗保健领域最大的挑战之一是对抗肿瘤。一些吩噻嗪对HEp - 2肿瘤细胞具有抗肿瘤活性。在本研究中,我们测试了三个系列的抗肿瘤效果,如10 - 无取代吩噻嗪、10 - [n -(邻苯二甲酰亚胺基)烷基] - 2 - 取代 - 10H - 吩噻嗪和1 -(氯乙基)- 3 -(2 - 取代 - 10H - 吩噻嗪 - 10 - 基)烷基 - 1 - 脲,其在C2位有H、Cl和CF3取代。吩噻嗪的半数组织培养感染剂量(TCID50)受C2位的H、Cl和CF3影响。吩噻嗪的三氟甲基衍生物显示出强效活性(R = CF3,TCID50 = 4.7微克),而吩噻嗪的氯衍生物(R = Cl,TCID50 = 62.5微克)效果相对较弱。在10 - [n -(邻苯二甲酰亚胺基)烷基] - 2 - 取代 - 10H - 吩噻嗪组中,10 - [3 -(邻苯二甲酰亚胺基)丙基] - 10H - 吩噻嗪(R = H,n = 3,TCID50 = 11.5微克)、10 - [4 -(邻苯二甲酰亚胺基)丁基] - 10H - 吩噻嗪(R = H,n = 4,TCID50 = 7.8微克)和10 - [3 -(邻苯二甲酰亚胺基)丙基] - 2 - 三氟甲基 - 10H - 吩噻嗪(R = CF3,n = 3,TCID50 = 11.5微克)非常有效。另一方面,10 - [3 -(邻苯二甲酰亚胺基)丙基] - 2 - 氯 - 10H - 吩噻嗪(R = Cl,n = 3,TCID50 = 75.0微克)、10 - [4 -(邻苯二甲酰亚胺基)丁基] - 2 - 氯 - 10H - 吩噻嗪(R = Cl,n = 4,TCID50 = 31.3微克)和10 - [4 -(邻苯二甲酰亚胺基)丁基] - 2 - 三氟甲基 - 10H - 吩噻嗪(R = CF3,n = 4,TCID50 = 50.0微克)的TCID50比10 - [4 -(邻苯二甲酰亚胺基)丁基] - 10H - 吩噻嗪(R = H,n = 4,TCID50 = 7.8微克)低约4 - 8倍。在六种1 -(氯乙基)- 3 -(2 - 取代 - 10H - 吩噻嗪 - 10 - 基)烷基 - 1 - 脲中,两种氯化合物,如1 -(2 - 氯乙基)- 3 -(2 - 氯 - 10H - 吩噻嗪 - 10 - 基)丙基 - 1 - 脲(R = Cl,n = 3,TCID50 = 6.3微克)、1 -(2 - 氯乙基)- 3 -(2 - 氯 - 10H - 吩噻嗪 - 10 - 基)丁基 - 1 - 脲(R = Cl,n = 4,TCID50 = 7.8微克)和1 -(2 - 氯乙基)- 3 -(2 - 三氟甲基 - 10H - 吩噻嗪 - 10 - 基)丁基 - 1 - 脲(R = CF3,n = 4,TCID50 = 7.8微克)具有显著活性。测试表明,2C位的取代明显影响抗HEp - 2肿瘤细胞活性;10N位脂肪族侧链的长度有助于抗肿瘤活性;并且除了10 - [4 -(邻苯二甲酰亚胺基)丁基] - 2 - 三氟甲基 - 10H - 吩噻嗪和1 -(氯乙基)- 3 -(2 - 氯 - 10H - 吩噻嗪 - 10 - 基)丁基 - 1 - 脲外,含丁烯基(-C4H8-)的衍生物的TCID50值低于含丙烯基(-C3H6-)的衍生物。